Renaissance Technologies LLC purchased a new position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS – Free Report) during the first quarter, HoldingsChannel.com reports. The fund purchased 40,457 shares of the company’s stock, valued at approximately $286,000.
Several other institutional investors have also modified their holdings of the business. Trifecta Capital Advisors LLC acquired a new position in shares of Alpha Tau Medical in the 4th quarter valued at approximately $48,000. Envestnet Asset Management Inc. acquired a new stake in Alpha Tau Medical during the 3rd quarter worth approximately $62,000. Bank of America Corp DE raised its holdings in Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after buying an additional 21,677 shares during the period. Wells Fargo & Company MN lifted its stake in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after buying an additional 17,500 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new position in Alpha Tau Medical in the first quarter valued at approximately $132,000. Institutional investors own 2.65% of the company’s stock.
Insider Buying and Selling
In related news, CFO Raphi Levy sold 32,500 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $10.83, for a total value of $351,975.00. Following the completion of the transaction, the chief financial officer owned 147,680 shares of the company’s stock, valued at approximately $1,599,374.40. This trade represents a 18.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 130,000 shares of company stock worth $1,519,143 in the last ninety days. Corporate insiders own 39.50% of the company’s stock.
Alpha Tau Medical Trading Up 1.5%
Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.36). The firm had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.14 million. As a group, analysts anticipate that Alpha Tau Medical Ltd. will post -0.92 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research analysts have recently weighed in on DRTS shares. Barclays upped their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. Benchmark reaffirmed a “buy” rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. HC Wainwright boosted their price objective on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Zacks Research raised shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, LADENBURG THALM/SH SH increased their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.80.
View Our Latest Stock Report on Alpha Tau Medical
About Alpha Tau Medical
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
Featured Stories
- Five stocks we like better than Alpha Tau Medical
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding DRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alpha Tau Medical Ltd. (NASDAQ:DRTS – Free Report).
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
